Skip to content
Screener

Design Therapeutics, Inc. DSGN Total Liabilities & Equity

Total Liabilities & Equity at other companies

ALN
Alnylam PharmaceuticalsALNY
$5.56B+21.7%
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
$857.16M-4.6%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$2.73B+25.8%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
$1.08B+49.8%
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
$381.23M+118%
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
$470.43M+41.1%

Other financials

Income statement

See full
Revenue-
Operating income-$19.7M+3.5%
Net income-$17.6M+0.4%
EPS (diluted)-$0.29+6.5%

Balance sheet

See full
Cash & equivalents$12.8M-6.6%
Total debt$2.7M+27.7%
Total equity$218.1M-4.3%
Total assets$230.4M-3.0%

Cash flow

See full
Operating cash flow-$16.4M+2.1%
CapEx--100%
Free cash flow-$16.4M+2.6%

Valuation

See full
Market cap$896.8M+227%
Enterprise value$886.76M+245%

Profitability

See full
Operating margin-3,685.8%
Net margin-3,663.7%

Returns & leverage

See full
Return on equity-31.3%+19.5pp
Debt / equity0.0×
Current ratio22.3×-6.1×

Where this comes from

Reported directly by Design Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Design Therapeutics, Inc.’s 10-Q, filed April 28, 2026.

Filed
Apr 28, 2026, 4:13 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-187063
Line itemMarch 31, 2026December 31, 2025
Commitments and contingencies (See Note 8)
Stockholders’ equity:
Common stock, $0.0001 par value; 200,000,000 shares authorized at March 31, 2026 and December 31, 2025; 62,441,429 and 60,398,051 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively66
Additional paid-in capital532,958509,100
Accumulated deficit(314,642)(297,006)
Accumulated other comprehensive (loss) income(268)403
Total stockholders’ equity218,054212,503
Total liabilities and stockholders’ equity$230,442$226,203

Item 1. Financial Statements.

FAQ

What is Design Therapeutics, Inc.'s total liabilities & equity?
Design Therapeutics, Inc. (DSGN) reported total liabilities & equity of $230.44M in Q1 2026.
How has Design Therapeutics, Inc.'s total liabilities & equity changed year-over-year?
Design Therapeutics, Inc.'s total liabilities & equity decreased by 3.0% year-over-year, from $237.48M to $230.44M.
What is the long-term trend for Design Therapeutics, Inc.'s total liabilities & equity?
Over 5 years (2020 to 2025), Design Therapeutics, Inc.'s total liabilities & equity has grown at a 44.0% compound annual growth rate (CAGR), from $36.52M to $226.2M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Design Therapeutics, Inc.'s total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude